Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

(NasdaqGM:APGE), SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease

Cryptocurrency Investment News: AAS Miner Launches the World’s First AI-Driven Bitcoin Mining Platform, Empowering Global Investors to Cope with Bitcoin Halving and ETF Regulatory Trends

Cryptocurrency Investment News: AAS Miner Launches the World's First AI-Driven Bitcoin Mining Platform, Empowering Global Investors to Cope with Bitcoin Halving and ETF Regulatory Trends Safe and compliant, in line with the Bitcoin halving and ETF wave, fully empowering global investors to steadily deploy digital wealth GlobeNewswire July 06, 2025 LONDON, UK, July 06, 2025

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 Webcast to be held Monday, July 7th at 8:00 a.m. ET GlobeNewswire July 06, 2025 SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) —

ROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

(NASDAQ:PEPG), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you

ROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG

ROSEN, SKILLED INVESTOR COUNSEL, Encourages PepGen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – PEPG GlobeNewswire July 06, 2025 NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PepGen Inc. (NASDAQ: PEPG) between March 7, 2024

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

(NYSE:DBI), NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public. SO WHAT:

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights GlobeNewswire July 06, 2025 NEW YORK, July 06, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims

Levi & Korsinsky Notifies Sarepta Therapeutics, Inc. (SRPT) Shareholders of Class Action Lawsuit and August 25, 2025 Deadline

NEW YORK, NY / ACCESS Newswire / July 6, 2025 / If you suffered a loss on your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sarepta-lawsuit-submission-form?prid=155680&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Scroll to Top